BioSpace13d
HEALEY ALS Trial Serves Up More Disappointment as Denali, AbbVie/Calico Fail
Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...
The Business Journals14d
Why biotech startup Tenvie sees promise in drugs from founders' old company
And Denali (Nasdaq: DNLI) is taking a "small" equity stake as well, Tenvie leaders said. What's more, 35-employee Tenvie is subleasing 15,000 square feet from Denali in South San Francisco.
ALS News Today14d
DNL343, fosigotifator fail HEALEY platform trial’s main goal in ALS
DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the ...
ETF Daily News15d
Denali Therapeutics (NASDAQ:DNLI) Shares Gap Down on Analyst Downgrade
Shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) gapped down prior to trading on Tuesday after JPMorgan Chase & Co. lowered their price target on the stock from $28.00 to $24.00.
Travel News15d
Holland America Line Announces $70M Multi-Year Expansion to Enhance Denali Lodge and Alaska Cruises
Holland America Line, the cruise line with the longest history of exploring Alaska, announced a $70 million capital investment that will expand guest capacity while elevating the line’s Denali ...
BioWorld15d
Sana soars on favorable type 1 diabetes phase I data
Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...
Investing15d
Denali Therapeutics stock maintains buy rating on FDA decision
On Wednesday, Stifel analysts maintained a Buy rating on shares of Denali Therapeutics Inc. (NASDAQ:DNLI) with a price target of $37.00. According to InvestingPro data, analysts remain highly bullish ...
Crain's Chicago Business15d
AbbVie and rival's ALS drugs both disappoint in study
In studies by Massachusetts General Hospital, the AbbVie-Calico collaborative drug and Denali Therapeutics' own drug failed to meet endpoints for treating amyotrophic lateral sclerosis, more widely ...
Investing15d
Denali Therapeutics stock maintains buy rating on FDA decision
On Wednesday, Stifel analysts maintained a Buy rating on shares of Denali Therapeutics Inc. (NASDAQ:DNLI) with a price target of $37.00. According to InvestingPro data, analysts remain highly ...
Yahoo Finance16d
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough ...
The Bakersfield Californian16d
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp ...
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough ...